Abstract
In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national studies, there appeared to be a small prolongation of survival but no increase in the proportion of long survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return. Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bloom H. J. Intracranial tumors: response and resistance to therapeutic endeavors, 1970-1980. Int J Radiat Oncol Biol Phys. 1982 Jul;8(7):1083–1113. doi: 10.1016/0360-3016(82)90056-6. [DOI] [PubMed] [Google Scholar]
- Cornbleet M. A., McElwain T. J., Kumar P. J., Filshie J., Selby P., Carter R. L., Hedley D. W., Clark M. L., Millar J. L. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer. 1983 Sep;48(3):329–334. doi: 10.1038/bjc.1983.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fingert H. J., Hochberg F. H. Megadose chemotherapy with bone marrow rescue. Prog Exp Tumor Res. 1984;28:67–78. doi: 10.1159/000408238. [DOI] [PubMed] [Google Scholar]
- Green S. B., Byar D. P., Walker M. D., Pistenmaa D. A., Alexander E., Jr, Batzdorf U., Brooks W. H., Hunt W. E., Mealey J., Jr, Odom G. L. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983 Feb;67(2):121–132. [PubMed] [Google Scholar]
- Henner W. D., Peters W. P., Eder J. P., Antman K., Schnipper L., Frei E., 3rd Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep. 1986 Jul;70(7):877–880. [PubMed] [Google Scholar]
- Phillips G. L., Wolff S. N., Fay J. W., Herzig R. H., Lazarus H. M., Schold C., Herzig G. P. Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol. 1986 May;4(5):639–645. doi: 10.1200/JCO.1986.4.5.639. [DOI] [PubMed] [Google Scholar]
- Walker M. D., Green S. B., Byar D. P., Alexander E., Jr, Batzdorf U., Brooks W. H., Hunt W. E., MacCarty C. S., Mahaley M. S., Jr, Mealey J., Jr Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980 Dec 4;303(23):1323–1329. doi: 10.1056/NEJM198012043032303. [DOI] [PubMed] [Google Scholar]
- Wolff S. N., Phillips G. L., Herzig G. P. High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system. Cancer Treat Rep. 1987 Feb;71(2):183–185. [PubMed] [Google Scholar]